White Plague Statistics in US 2026 | Cases, Deaths & Key Facts

What is White Plague?

The White Plague — tuberculosis — is one of the oldest and most persistent infectious diseases in human history, and in 2026, it is staging a documented resurgence inside the borders of a country that once believed it was on an irreversible path to elimination. Tuberculosis earns its grim nickname from the ghostly pallor that the disease historically imposed on its victims — a wasting, progressive destruction of the lungs that drained colour, weight, and life across centuries before antibiotics made it treatable. The disease reclaimed its global title as the world’s deadliest single infectious agent in 2023, briefly surrendered to COVID-19 in the pandemic’s opening years, and in the United States, it has now reversed three decades of relentless decline. The CDC’s most recent provisional surveillance report, released on March 23, 2026, confirmed 10,260 TB cases in 2025 — the sixth consecutive year in which case counts have remained elevated above pre-pandemic baselines, and in which the pandemic’s “rebound effect” of reactivating untreated latent infections continues to drive new disease. TB is not a relic. It is a living, airborne, antibiotic-resistant, and currently accelerating public health threat in the United States in 2026.

What makes the White Plague’s 2026 comeback so sobering is the combination of forces propelling it — none of which has been fully addressed. The COVID-19 pandemic dismantled years of TB surveillance infrastructure: screening programs shut down, contact tracing resources were redeployed, clinicians missed or delayed diagnoses as patients presenting with cough and fatigue were triaged as potential COVID cases, and newly arrived immigrants who carried latent TB infections from high-burden countries went unscreened. The result was a pandemic-era underdiagnosis bubble that is now popping in slow motion across American communities, with latent infections acquired years or decades ago now activating as immune systems age and weaken. Meanwhile, the FY2026 federal budget proposed a $228 million reduction to TB programs, and a Congressional proposal would fold dedicated TB funding into a consolidated block grant — exactly the kind of structural accountability erosion that public health experts warn historically precedes outbreaks. The CDC’s own elimination target — fewer than 1 case per 1,000,000 population — has never felt more distant than it does in 2026.

Interesting Facts: White Plague (TB) Statistics in the US 2026

Source: CDC Provisional 2025 Tuberculosis Data (March 23, 2026), CDC Reported Tuberculosis in the United States 2024 (December 19, 2025), Fox News / WFMD / AOL (March 29, 2026), CIDRAP (March 24, 2026), The Edge of Epidemiology Substack (March 27, 2026), WHO Fact Sheet on Tuberculosis, CDC NCHHSTP Director’s Letter (March 24, 2026)

The interesting facts above frame a disease that defies easy categorisation in 2026. It is, simultaneously, more controlled than at any point in recorded American history — down 56% in cases and 68% in rate since 1989 — and more concerning than it has been in more than a decade, with four consecutive annual increases from 2021 to 2024 erasing hard-won surveillance gains. The 20:1 rate disparity between non-US-born and US-born populations is the defining structural feature of American tuberculosis epidemiology: the country’s success in domestically suppressing TB transmission is genuine, but its porous relationship with high-burden global TB epidemics makes the disease persistently re-imported with every wave of immigration and international travel. The Kansas City outbreak of 2024–2025 — the largest the CDC has recorded since it began tracking outbreaks nationally — was not caused by a new strain or a novel transmission pathway; it was caused by a combination of public health workforce depletion during COVID, housing instability, and delayed diagnosis, all factors that are present in dozens of other American cities and counties right now.

The 13 million Americans living with latent TB infection and the fact that more than 80% of active US cases are reactivations rather than new transmissions is the piece of the White Plague story that receives the least public attention and carries the most policy significance. The US is not primarily fighting active, infectious TB being passed person-to-person on subway cars and in offices — it is fighting a slow-burning time-bomb of decades-old latent infections in an aging population, whose immune systems are less capable of keeping the dormant bacteria permanently suppressed. As that population ages, as immunosuppressive therapies for cancer and autoimmune diseases proliferate, and as HIV/AIDS coinfection continues in certain communities, the 5–10% lifetime activation risk for each of those 13 million latent infections becomes an ever-present actuarial certainty. The question is not whether more of those will activate — it is whether the funding and infrastructure exist to find, treat, and prevent them.

US White Plague Case Counts 2026 | Historical Trend Data

Source: CDC Reported Tuberculosis in the United States, 2024 (December 19, 2025); CDC Provisional 2025 Tuberculosis Data (March 23, 2026); CDC Emerging Infectious Diseases, March 2026 (COVID-19 and TB analysis); Edge of Epidemiology Substack (March 27, 2026)

The historical trend data for White Plague (TB) cases in the US is one of the most instructive public health charts in American epidemiology — a 30-year story of disciplined decline that makes the post-2020 reversal all the more striking. From the 1993 peak of 26,673 cases — driven by the HIV epidemic’s immune-destroying synergy with TB — through a sustained period of decline built on improved treatment, latent infection identification, and international travel screening, the US trajectory was so consistent that the CDC’s elimination goal of fewer than 1 case per million seemed, by the late 2010s, genuinely achievable within a generation. The 2019 baseline of approximately 8,916 cases was the lowest peacetime figure in modern American surveillance history. Then COVID-19 arrived, and in a single year, the system that had taken 30 years to build was partially dismantled. The 7,170 cases in 2020 looked like progress in the data — but it was an artifact of missed diagnoses and disrupted screenings, not a true decline. The debt came due from 2021 onward, with four consecutive annual increases restoring the case count past the 10,000 threshold for the first time since 2012.

The 2025 provisional data’s 1% decline — from 10,395 to 10,260 — is being read cautiously by public health experts rather than celebrated. CIDRAP’s March 24, 2026 report specifically highlighted that the Kansas City metro area’s dramatic decline in reported cases (after its 2024 outbreak was declared over in November 2025) is a significant statistical driver of the national dip — meaning the underlying national trend may not be as improved as the top-line number suggests. The CDC’s own commentary, published by NCHHSTP Director on March 24, 2026, was notably measured: “TB cases in the United States remained elevated over pre-pandemic levels.” The critical phrase there is “remained elevated” — not declining to pre-pandemic baselines, not approaching elimination. The CDC elimination target set in 1989 — fewer than 1 case per million population, or approximately 340 cases nationally — remains so distant from today’s 10,260 that it functions less as an operational target and more as a directional aspiration for which current policy architecture is wholly insufficient.

White Plague Demographics in the US 2026 | Who Gets TB & Why

Source: CDC Reported Tuberculosis in the United States, 2024 (December 19, 2025); CDC Provisional 2025 Tuberculosis Data (March 23, 2026); The Edge of Epidemiology Substack (March 27, 2026); Vax-Before-Travel.com (TB Outbreaks report, 2026)

The demographic data on White Plague in the US in 2026 tells a story of profound bifurcation. On one track, the decades-long domestic TB control effort is genuinely working: US-born TB cases have fallen 87% since 1993, from 17,422 to 2,298 — one of the great public health achievements in American history. On the other track, the country is unable to insulate itself from the global TB burden that arrives with every flight, every border crossing, and every refugee settlement. The 20:1 rate disparity between non-US-born and US-born individuals does not reflect a failure of domestic TB programs — it reflects the reality that India, Indonesia, China, the Philippines, and Pakistan together account for more than 50% of global TB disease, and the US receives immigrants and refugees from those high-burden countries continuously. Non-US-born individuals who carry latent TB infections do not pose an immediate transmission risk — latent TB is not contagious — but the 5–10% lifetime activation risk means that without systematic screening and treatment of latent infection in newly arrived populations, a percentage of those cases will inevitably activate years or decades later.

The geographic concentration of US TB cases is the data point most useful for understanding where the public health burden falls and why. California, Texas, New York, and Florida together accounting for approximately 50% of all national TB cases is not coincidental — these are the four largest states by population, the four largest gateways for international immigration and travel, and the four states with the most densely populated urban corridors where transmission, if it occurs, can escalate quickly. Alaska’s 12.3 per 100,000 rate — the highest in the continental US — reflects a combination of Alaska Native population health disparities, geographic barriers to healthcare access, and limited public health infrastructure in remote communities. The finding that persons 65 and older were the only age group to see a rate increase in 2025 is consistent with the reactivation biology of latent TB: as immunity wanes with age, decades-old infections that have been suppressed since youth begin to break through, producing active disease in exactly the demographic that the broader healthcare system is simultaneously least equipped to rapidly diagnose.

White Plague Drug Resistance Statistics in the US 2026 | MDR & XDR-TB

Source: CDC Reported Tuberculosis in the United States, 2024 — Drug Resistance tables (December 16–19, 2025); CDC Drug-Resistant TB clinical overview (updated January 2025); CDC Yellow Book 2026 edition (NCBI, April 2025); WHO Global Tuberculosis Report 2025 (November 2025); The Lancet Microbe — BPaLM price reduction report (April 2025)

The drug-resistance data for White Plague in the US in 2026 reflects both the strengths of American TB treatment protocols and the global threats they must continuously guard against. The domestic numbers are, by global standards, remarkably controlled: MDR-TB at 1.5% of tested cases, with only 5 XDR-TB cases in the entire country in 2024, confirms that the CDC and IDSA’s stringent treatment guidelines — including directly observed therapy for high-risk cases and diligent follow-up by public health personnel — are preventing the treatment failures and incomplete courses that generate drug-resistant strains. The updated 2025 consolidated treatment guidelines from ATS/CDC/ERS/IDSA represent the latest iteration of this clinical infrastructure, integrating new molecular drug susceptibility testing alongside traditional culture-based methods to catch resistance earlier and more reliably. The critical vulnerability is importation: MDR-TB does not develop in the US at significant rates — it arrives from high-burden countries where drug-resistant strains are endemic, which is why the 1.7–1.5% MDR rate among non-US-born TB patients is consistently higher than the near-zero rate among US-born cases.

The global MDR-TB picture in 2025–2026 is where the data becomes genuinely alarming and where the US situation must be understood in its proper context. Only 2 in 5 people with MDR-TB globally accessed treatment in 2024 — meaning approximately 60% of the world’s MDR-TB patients were untreated, continuing to transmit, and continuing to generate the resistant strains that eventually find their way to the US through immigration and travel. The 47% reduction in the BPaLM treatment regimen cost — from $588 in December 2022 to $310 in April 2025 — is a genuine breakthrough that the Stop TB Partnership and TB Alliance deserve credit for. But as Treatment Action Group’s Lindsay McKenna warned in April 2025, lower drug prices alone will not substantially improve global MDR-TB control “when programs are being squeezed from every direction” — a comment that became even more pointed after US foreign aid cuts in early 2025 began affecting TB programs in the highest-burden countries. When those programs weaken, more MDR-TB develops, spreads, and eventually arrives at US borders — a feedback loop that no domestic clinical guideline can fully interrupt.

White Plague Outbreaks in the US 2026 | Notable Cases & Cluster Data

Source: CDC Provisional 2025 TB Data (March 23–24, 2026); CIDRAP (March 24, 2026); Edge of Epidemiology Substack (March 27, 2026); Post-Millennial / EndTimes Prophecy Watch (March 26, 2026); CDC surveillance report 2024 reporting areas table (December 19, 2025)

The outbreak data for White Plague in the US in 2026 places the abstract case count statistics into the specific geographic and community contexts where the disease is actually spreading. The Kansas City mega-outbreak — 68 active cases, 91 latent infections, and 2 deaths across 22 months — is the most clinically documented cluster in recent American TB history, and its duration illustrates exactly why TB outbreaks are so difficult to contain once established. TB’s incubation and progression timeline is measured in weeks to years, not hours to days — an infected person may not develop active disease for months after exposure, meaning contact tracing requires identifying, testing, and following up hundreds of individuals across extremely long time windows. The Wyandotte County TB program was acknowledged as chronically understaffed before the outbreak began — a circumstance that is not unique to Kansas City but is shared by local health departments across the country that lost TB-trained staff during the COVID-19 years and have not fully replaced them.

The geographic distribution of 2026 White Plague outbreaks traces the exact contours of demographic vulnerability and healthcare access gaps in American society. Alaska’s 12.2 per 100,000 rate reflects the combination of Alaska Native communities with elevated poverty rates and limited healthcare infrastructure in remote settings. New York City’s 967 cases and 9.8 per 100,000 rate reflect the intersection of high-density living, a large immigrant population from high-burden countries, and pockets of unhoused individuals for whom consistent TB treatment adherence is logistically near-impossible without dedicated case management. The five jurisdictions that saw 50%+ case count increases in 2024 — not publicly named in CDC data tables but representing extreme single-year surges — signal either genuine transmission amplification or, more likely, a sudden correction of pandemic-era underdiagnosis as delayed cases were finally confirmed. In either scenario, the implication is the same: there are almost certainly more active TB cases in the US right now than the national surveillance system has detected.

Global White Plague Statistics 2026 | US vs. World Context

Source: WHO Global Tuberculosis Report 2025 (November 2025); WHO Tuberculosis Fact Sheet (March 2026); Fox News / WFMD (March 29, 2026); Edge of Epidemiology Substack (March 27, 2026); UK Health Security Agency UKHSA 2024 data; Cambridge Journal of Benefit-Cost Analysis (TB cost-benefit study, 2023); Vax-Before-Travel (February 2026)

The global White Plague statistics for 2026 provide the essential context for understanding the US situation — and they make the domestic picture look simultaneously reassuring and critically precarious. The US rate of 3.0 per 100,000 sitting approximately 40 times below the global average of 131 per 100,000 confirms that the American TB control infrastructure is genuinely world-class by any comparative standard. The 1.23 million global TB deaths in 2024 and 10.7 million new cases position the disease as the dominant infectious killer on Earth — more deadly than HIV, malaria, or any vector-borne disease — and the US is, by global standards, largely shielded from that burden through its wealth, healthcare infrastructure, and historical investment in TB elimination. The finding that global TB efforts have saved an estimated 83 million lives since 2000 and that each dollar invested in TB control yields $46 in economic benefits frames TB funding not as a charity expenditure but as one of the most efficient economic investments in all of public health.

The proposed FY2026 federal budget cut of $228 million from TB programs — reducing the allocation to $178 million against an FY2024 baseline of approximately $406 million — is the most consequential policy development in US TB control since the COVID-era disruptions. The Edge of Epidemiology’s March 2026 analysis specifically estimated that the loss of US bilateral health aid alone would result in 2.5 million additional pediatric TB cases and 340,000 additional child deaths in low- and middle-income countries between 2025 and 2034. But the domestic implications are equally serious: when US-funded TB programs in high-burden countries weaken, more MDR-TB develops, more cases go undetected among individuals who will subsequently travel to or immigrate to the US, and the country’s own domestic burden increases. The UK’s 13% case increase in 2024 — following years of National Health Service capacity reductions and program cuts — is the cautionary data point from a comparable high-income nation that cut too aggressively and is now managing the consequence. The White Plague does not reward complacency, and 2026’s data makes that plainer than it has been in over a decade.

White Plague Treatment & Diagnosis Statistics in the US 2026

Source: CDC Clinical Overview: TB Disease (2026); CDC Yellow Book 2026 (NCBI); Fox News / WFMD (March 29, 2026); Vax-Before-Travel.com TB vaccines (February 2026); WHO Tuberculosis Fact Sheet (March 2026); ATS/CDC/ERS/IDSA 2025 consolidated TB treatment guidelines

The treatment and diagnosis landscape for White Plague in the US in 2026 represents a field in active evolution — one where decades-old antibiotic regimens are finally being supplemented by new shorter courses, better diagnostic tools, and the most promising pipeline of TB vaccine candidates since the BCG was developed over a century ago. The arrival of the BPaLM regimen as the WHO-recommended standard for MDR-TB — compressing what was once an 18–20 month ordeal into a 6-month all-oral course — is the most significant clinical advance in TB treatment in a generation, and its 47% price reduction to $310 per regimen means it is increasingly accessible in the settings that need it most. For drug-susceptible TB, the move toward 4-month regimens using rifapentine and moxifloxacin — approved in 2023 following TB Alliance trials — reduces the adherence burden and the duration of side effects that cause patients to abandon treatment prematurely, the very behavior that generates drug resistance in the first place.

The TB vaccine pipeline in 2026 is the most substantive in the disease’s 130-year history of scientific engagement. With six candidates in Phase III clinical trials — including M72/AS01E, which showed 54% efficacy against active TB in latently infected adults in a landmark 2019 trial — the prospect of a new TB vaccine reaching licensure in the late 2020s or early 2030s has moved from theoretical to genuinely plausible. For the US, a new TB vaccine with adult efficacy would transform the latent infection management problem entirely: instead of finding, testing, and treating each of the 13 million Americans with latent TB individually, a licensed vaccine could be deployed systematically in high-risk communities to prevent activation. The BCG’s supply constraint in February 2026 — with Merck’s TICE® BCG strain the only FDA-approved formulation and global demand exceeding supply — is a reminder of how fragile the current prevention infrastructure is and why the new vaccine pipeline matters so urgently for both global and domestic TB control in the years ahead.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE